Key result
The use of recombinant human soluble thrombomodulin for DIC increased from 25.1% in 2010 to 56.8% in 2012 (OR 4.34; 95% CI 3.94-4.79; P<.001), with large hospital size being a significant factor.
Population
14,324 patients with infectious disease-associated disseminated intravascular coagulation referred to 1,041…
Design
Cohort
Authors
Loading...
rhs-TM use rose sharply for infectious DIC; leaves open whether this shift improves outcomes or reflects practice variation.
Observational (n=14,324)
Yes
Odds Ratio: 4.34 (95% CI 3.94–4.79)
Absolute Event Rate: 56.8% vs 25.1%
p-value: p=<.001
The use of recombinant human soluble thrombomodulin for infectious disease-associated DIC dramatically increased in Japan from 2010 to 2012, particularly in large hospitals.
Murata et al. (2015) conducted an observational in infectious disease-associated disseminated intravascular coagulation (DIC) (n=14,324). Study period (2012) vs. Study period (2010) was evaluated on Use of recombinant human soluble thrombomodulin (rhs-TM) (OR 4.34, 95% CI 3.94-4.79, p=<.001). The use of recombinant human soluble thrombomodulin for DIC increased from 25.1% in 2010 to 56.8% in 2012 (OR 4.34; 95% CI 3.94-4.79; P<.001), with large hospital size being a significant factor.
Synapse has enriched one closely related paper. Consider it for comparative context: